Critical illness-related corticosteroid insufficiency medical therapy

Revision as of 16:16, 20 September 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search

Critical illness-related corticosteroid insufficiency Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Critical illness-related corticosteroid insufficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Critical illness-related corticosteroid insufficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Critical illness-related corticosteroid insufficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Critical illness-related corticosteroid insufficiency medical therapy

CDC on Critical illness-related corticosteroid insufficiency medical therapy

Critical illness-related corticosteroid insufficiency medical therapy in the news

Blogs on Critical illness-related corticosteroid insufficiency medical therapy

Directions to Hospitals Treating Critical illness-related corticosteroid insufficiency

Risk calculators and risk factors for Critical illness-related corticosteroid insufficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

In adults with septic shock and refractory hypotension despite resuscitation with intravenous fluids and vasopressors, hydrocortisone is the preferred corticosteroid. It can be divided in several doses or administered as a continuous infusion.[1] Fludrocortisone is optional in CIRCI, and dexamethasone is not recommended.[2] Little evidence is available to judge when and how corticosteroid therapy should be stopped; guidelines recommend tapering corticosteroids when vasopressors are no longer needed.

Corticosteroid treatment has also been suggested as an early treatment option in patient with acute respiratory distress syndrome. Steroids have not been shown beneficial for sepsis alone.[3] Historically, higher doses of steroids were given, but these have been suggested to be harmful compared to the lower doses which are advocated today.[4]

In the CORTICUS study, hydrocortisone hastened the reversal of septic shock, but did not influence mortality, with an increased occurence of septic shock relapse and hypernatremia.[5] The latter findings tempered enthusiasm for the broad use of hydrocortisone in septic shock. Prior to this study, several other smaller studies showed beneficial effects of long courses of low doses of corticoid.[6][7][8][9][10][11][12] Several factors (such as lack of statistical power due to slow recruitment) could have led a false-negative finding on mortality in the CORTICUS study; thus, more research is needed.[13]

References

  1. name=http://www.ncbi.nlm.nih.gov/pubmed?term=18496365
  2. name=http://www.ncbi.nlm.nih.gov/pubmed?term=18158437
  3. Lefering R, Neugebauer EA (1995). "Steroid controversy in sepsis and septic shock: a meta-analysis". Crit. Care Med. 23 (7): 1294–303. PMID 7600840. Unknown parameter |month= ignored (help)
  4. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004). "Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose". Ann. Intern. Med. 141 (1): 47–56. PMID 15238370. Unknown parameter |month= ignored (help)
  5. name=http://www.ncbi.nlm.nih.gov/pubmed?term=18184957
  6. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y (2004). "Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis". BMJ. 329 (7464): 480. doi:10.1136/bmj.38181.482222.55. PMC 515196. PMID 15289273. Unknown parameter |month= ignored (help)
  7. Briegel J, Forst H, Haller M; et al. (1999). "Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study". Crit. Care Med. 27 (4): 723–32. PMID 10321661. Unknown parameter |month= ignored (help)
  8. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998). "Reversal of late septic shock with supraphysiologic doses of hydrocortisone". Crit. Care Med. 26 (4): 645–50. PMID 9559600. Unknown parameter |month= ignored (help)
  9. Oppert M, Schindler R, Husung C; et al. (2005). "Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock". Crit. Care Med. 33 (11): 2457–64. PMID 16276166. Unknown parameter |month= ignored (help)
  10. Yildiz O, Doganay M, Aygen B, Güven M, Keleştimur F, Tutuû A (2002). "Physiological-dose steroid therapy in sepsis [ISRCTN36253388]". Crit Care. 6 (3): 251–9. PMC 125315. PMID 12133187. Unknown parameter |month= ignored (help)
  11. Keh D, Boehnke T, Weber-Cartens S; et al. (2003). "Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study". Am. J. Respir. Crit. Care Med. 167 (4): 512–20. doi:10.1164/rccm.200205-446OC. PMID 12426230. Unknown parameter |month= ignored (help)

Template:WH Template:WS